Integral Health Asset Management LLC Increases Stock Position in Rezolute, Inc. (NASDAQ:RZLT)

Integral Health Asset Management LLC boosted its position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 100.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 500,000 shares of the company's stock after purchasing an additional 250,000 shares during the period. Integral Health Asset Management LLC owned about 0.86% of Rezolute worth $2,450,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new stake in Rezolute during the third quarter worth approximately $42,000. Alpine Global Management LLC bought a new stake in shares of Rezolute in the fourth quarter worth $54,000. Charles Schwab Investment Management Inc. lifted its holdings in Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after buying an additional 9,000 shares during the period. Oxford Asset Management LLP acquired a new position in Rezolute in the fourth quarter valued at $154,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Rezolute during the fourth quarter valued at about $168,000. Institutional investors own 82.97% of the company's stock.

Rezolute Trading Up 0.3%

Shares of NASDAQ:RZLT traded up $0.01 during trading on Friday, reaching $3.57. The stock had a trading volume of 1,113,556 shares, compared to its average volume of 629,641. The firm's 50-day simple moving average is $3.24 and its 200 day simple moving average is $4.30. The company has a market capitalization of $216.11 million, a P/E ratio of -2.93 and a beta of 1.01. Rezolute, Inc. has a one year low of $2.22 and a one year high of $6.19.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Equities research analysts forecast that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Craig Hallum upgraded shares of Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. JMP Securities raised their price objective on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research report on Thursday, February 13th. Wedbush reaffirmed an "outperform" rating and set a $12.00 target price on shares of Rezolute in a report on Wednesday. Finally, HC Wainwright restated a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a research report on Monday, April 28th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $12.14.

Insider Transactions at Rezolute

In other Rezolute news, CEO Nevan C. Elam acquired 12,302 shares of the company's stock in a transaction on Thursday, March 27th. The shares were bought at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the purchase, the chief executive officer now owns 224,119 shares in the company, valued at $638,739.15. This trade represents a 5.81% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Wladimir Hogenhuis bought 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was purchased at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the acquisition, the director now owns 77,267 shares of the company's stock, valued at approximately $363,154.90. This represents a 14.87% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 39,060 shares of company stock worth $130,694. 18.39% of the stock is currently owned by insiders.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.